Ironwood Pharmaceuticals Inc. Class A (IRWD) Peer Comparison

$3.70

$-0.05 (-1.33%)

As on 08-Oct-2026 11:38EDT

Market cap

$601 Mln

Revenue (TTM)

$389 Mln

P/E Ratio

4.7

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	601	16,732	14,995	14,468	12,469
Revenue ($ Mln)	389	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	129.87	491.50	755.85	860.62	413.60
Net Margin (%)	33.36	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	4.73	35.22	17.89	18.36	31.39
Price-To-Book	2.59	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	389.32	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	1.38	1,982.07	103.47	85.67	363.07
Gross Profit	296.15	760.62	588.53	2,236.43	1,091.18
Operating Expenses	152.32	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	236.08	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	207.38	598.92	101.11	1,035.47	583.34
Provision for Tax	77.51	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	129.87	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-161.84	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	414.12	187.89	384.48	288.55	2,089.43
Current Liabilities	32.85	1,435.43	464.70	361.93	344.44
Total Liabilities	396.90	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	85.93	1,006.90	895.24	1,243.41	1,644.38
Current Assets	199.20	1,050.29	1,389.84	1,250.82	933.02
Total Assets	396.90	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	396.87	120.10	449.89	165.93	2,146.65
Net Current Assets	166.35	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	127.04	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	-0.03	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	0.22	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	7.57	53.56	-30.01	32.82	15.61
ROE (%)	-8.53	110.09	163.18	42.98	430.03
ROA (%)	29.07	15.64	31.68	29.32	16.19
EBIT Margin (%)	61.66	21.13	5.73	41.23	36.28
Net Margin (%)	33.36	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	26.19	24.67	114.85	9.23	41.15
EBIT Growth (%)	151.81	18.70	136.39	27.56	-14.99
Net Profit Growth (%)	1,747.03	17.50	378.76	42.89	-25.78
EPS Growth (%)	1,649.75	26.84	353.27	50.42	-23.48
Book Value Growth (%)	48.67	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	24.94	36.06	-59.76	15.79	24.99
Price / Book Value	-2.29	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	9.38	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	-2.38	0.00	0.27	0.00	13.50
Short term debt to equity ratio	-0.02	0.00	0.05	0.00	1.46
Current Ratio	6.06	0.73	2.99	3.46	2.71
Quick Ratio	6.06	0.73	2.32	3.38	2.31
Interest Coverage	7.35	--	1.62	--	29.73

Operating Efficiency Ratios

	Ironwood Pharmaceuticals Inc. Class A (IRWD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	28.96	15.88	21.25	13.74	27.40
Asset Turnover	0.87	0.89	0.44	0.83	0.65
Receivable days	79.32	50.42	85.52	43.48	98.04
Inventory Days	--	--	1,056.70	96.17	190.34
Payable days	487.87	6.26	331.01	147.97	18.62
Cash Conversion Cycle	--	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly